Modular Medical raises $4.68M in underwritten public offering of stock and warrants

Modular Medical, Inc.

Offered 12,173,000 shares of common stock and warrants for 6,086,500 shares at combined price of $0.77 per unit.
Effective price of $0.38 per share and $0.01 per warrant; warrants exercisable at $0.45, expire in 5 years.
Gross proceeds of $4.68M; net proceeds to fund operations, working capital, and general corporate purposes.
Underwriter Newbridge Securities granted 30-day over-allotment option for up to 15% additional shares/warrants.
Directors and executive officers subject to 60-day lock-up; company subject to 90-day lock-up.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Modular Medical, Inc. entered into Underwriting Agreement with Newbridge Securities Corporation valued at approximately $4.68 million (effective 2025-12-10).

Action: entry
Agreement: underwriting
Counterparty: Newbridge Securities Corporation
Value: approximately $4.68 million
Effective: 2025-12-10

Exact text from the filing

On December 10, 2025, Modular Medical, Inc. (the “Company”) entered into an Underwriting Agreement (the “Agreement”) with Newbridge Securities Corporation (the “Underwriter”), relating to a firm commitment underwritten offering (the “Offering”) of (i) 12,173,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), referred to as the “Firm Shares,” and (ii) accompanying warrants exercisable to purchase up to 6,086,500 shares of Common Stock (the “Warrants”), referred to as the “Firm Warrants.”

View on SEC.gov

255 material agreements filed in the last 30 days. Browse all material agreements →

Modular Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-120759

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.